Current market catalysts

Here's Why You Should Retain ZETA Stock in Your Portfolio Now

Zeta Global (ZETA) reported Q2 2026 revenues of $442.8 million, up 43.5% year-over-year with 28% organic growth. The company raised 2026 guidance to $1.82 billion in revenue and $405 million in adjusted EBITDA, marking its 20th consecutive beat-and-raise quarter. However, rising cost of revenues (41% of sales, up 300 basis points) due to higher-cost social channel adoption and agency exposure present margin pressures. The stock holds a Zacks Rank #3 (Hold) rating.

Dan Ives Says the AI Trade Is Only in the "Third Inning." Should Investors Stay Long AI Stocks?

Dan Ives argues the AI revolution is still in early stages, comparing it to the third inning of baseball. The focus is shifting from GPU purchases to monetizing AI across infrastructure, cloud platforms, and software. Companies with real AI revenue, clear ecosystem roles, and strong customer bases are positioned best for long-term growth.

Bloom Energy Is Down 38% From Its High. Forecasts Suggests a $5,000 Investment Now Will Be Worth This Much by August 2027.

Bloom Energy has surged 149% in 2026 but remains 38% below its $351 52-week high. With a median analyst price target of $295, a $5,000 investment could reach approximately $6,782 by August 2027, representing a 35.6% gain. The company benefits from AI-driven demand for on-site power solutions and recently exceeded $1 billion in quarterly revenue for the first time, though analysts caution that future gains may moderate as the company matures.

ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against ARS Pharmaceuticals (NYSE:SPRY) for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product 'neffy' with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to disclose risks of delays that would impact summer and back-to-school seasons. Investors who purchased ARS securities between March 9 and June 24, 2026 can apply to be lead plaintiff by October 5, 2026.

Bragar Eagel & Squire, P.C. Urges Wise Group plc (WSE) Investors to Contact the Firm Before the September 29th Lead Plaintiff Deadline

A class action lawsuit has been filed against Wise Group plc for allegedly making false and misleading statements about its regulatory risks, specifically regarding deficient anti-money laundering efforts and insufficient terrorism financing prevention measures ahead of its NASDAQ debut. Investors who purchased Wise securities between May 11, 2026 and July 23, 2026 have until September 29, 2026 to apply as lead plaintiff.

PENTAIR CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Pentair plc Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 2nd

A class action lawsuit has been filed against Pentair plc for allegedly failing to disclose significant inventory destocking in its Pool channel between April 28, 2026 and July 14, 2026, which adversely affected sales and operating income. The company's positive statements about its business and prospects are alleged to be materially misleading. Investors who purchased Pentair securities during the class period have until October 2, 2026 to apply for lead plaintiff status.

Deadline Alert: GPGI, Inc. (GPGI) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action lawsuit has been filed against GPGI, Inc. (formerly CompoSecure) alleging that defendants made materially false statements and failed to disclose that the value of acquired company Husky Technologies was overstated. The complaint claims defendants concealed that Husky was not on track to meet revenue and EBITDA targets, and that a primary motivation was generating fees for Resolute Holdings rather than creating shareholder value. The stock declined significantly following negative earnings reports in March and May 2026. Investors who purchased GPGI securities between November 3, 2025 and May 6, 2026 have until September 14, 2026 to file a lead plaintiff motion.

Datavault AI Inc. Investors Have Until October 5th to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role

A class action lawsuit has been filed against Datavault AI Inc. (NASDAQ: DVLT) for allegedly making materially false and misleading statements regarding corporate partnerships, trading volume on its platform, and undisclosed connections to a convicted felon. Investors who purchased securities between September 4, 2024 and October 30, 2025 have until October 5, 2026 to apply as lead plaintiff.

Bragar Eagel & Squire, P.C. Reminds Blaize Holdings, Inc. Investors to Contact the Firm Regarding Their Rights Before October 5th

A class action lawsuit has been filed against Blaize Holdings, Inc. (NASDAQ: BZAI) in the U.S. District Court for the Central District of California. The lawsuit alleges that Blaize made false and misleading statements regarding announced transactions with unequipped entities, improper revenue recognition, and materially false public statements. Investors who purchased Blaize securities between July 18, 2025 and April 28, 2026 have until October 5, 2026 to apply to be appointed as lead plaintiff.

Why ServiceNow Rallied Today

ServiceNow stock rallied 9.2% following Salesforce's strong earnings report, which alleviated fears of a 'SaaS-pocalypse' from agentic AI. Salesforce reported 10.8% revenue growth, beat EPS estimates by 80%, and showed its AI-infused Agentforce features growing at 210% annualized revenue run rate. Both companies are positioned as platforms that will collaborate with AI rather than be disrupted by it, with Salesforce announcing a partnership with Anthropic called 'Claudeforce.'

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

Berkshire Hathaway holds nearly 45% of DaVita, a kidney dialysis healthcare company, representing its largest proportional equity stake—larger than Apple or American Express. Despite recent modest sell-offs in 2025, DaVita has surged over 56% year-to-date, driven by strong Q1 earnings that beat analyst expectations. The company offers consistent profitability, revenue growth, and an attractive forward P/E ratio of just over 12.

Music Beats Cancer Launches “Thumbs Up for a Cure” to Support the Next Generation of Childhood Cancer Treatments

Music Beats Cancer, a nonprofit supporting cancer-fighting biotechnologies, will host its inaugural 'Thumbs Up for a Cure' event on September 5 at LongHouse Reserve in East Hampton. The event brings together families, biotech innovators, philanthropists, and artists to advance childhood cancer treatments. A unique Kids Q&A will feature children evaluating promising technologies from biotech companies developing treatments for difficult-to-treat pediatric cancers including DIPG.

Archer Aviation vs. Space Exploration Technologies: Which High Flying Stock Is a Better Buy in 2026?

Archer Aviation and SpaceX represent two different aerospace plays with vastly different maturity levels. Archer is pre-commercial with $300K revenue and $618M losses, pursuing FAA certification for eVTOL aircraft. SpaceX generates $18.7B in revenue but reported a $5B net loss in FY2025 due to massive capital requirements. The article concludes SpaceX is the wiser long-term choice despite both companies' negative cash flows, citing SpaceX's established Starlink business and market support versus Archer's high valuation multiples and regulatory uncertainties.

Rubrik Q2 Adj. EPS $0.22 Beats $0.04 Estimate, Sales $427.260M Beat $396.278M Estimate

Rubrik (NYSE:RBRK) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.04 by 450 percent. This is a 833.33 percent increase over losses of $(0.03) per share from the same

PagerDuty Sees Q3 Adj EPS $0.34-$0.36 vs $0.34 Est; Sees Sales $123.000M-$125.000M vs $124.255M Est

PagerDuty (NYSE:PD) is looking for Q3 Adj EPS of $0.34-$0.36 vs $0.34 analyst estimate. sees sales of $123.000 million-$125.000 million vs $124.255 million analyst estimate.

Alerus Financial Announces Buyback Program Of Up To 1,250,000 Shares

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000903419/000143774926029099/alrs20260825_8k.htm

Kazia Therapeutics Commences Offering Of American Depositary Shares; Terms Undisclosed

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity

Elastic shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates. Also, the company raised its FY27 guidance.

Rubrik Raises FY2027 Adj EPS Guidance from $0.25-$0.35 to $0.47-$0.53 vs $0.31 Est; Raises FY2027 Sales Guidance from $1.638B-$1.648B to $1.685B-$1.693B vs $1.645B Est

Rubrik (NYSE:RBRK) raises FY2027 Adj EPS guidance from $0.25-$0.35 to $0.47-$0.53 vs $0.31 analyst estimate. Raises FY2027 sales outlook from $1.638 billion-$1.648 billion to $1.685 billion-$1.693 billion vs $1.645

Iris Energy Q4 Sales $137.200M Miss $142.320M Estimate

Iris Energy (NASDAQ:IREN) reported quarterly sales of $137.200 million which missed the analyst consensus estimate of $142.320 million by 3.60 percent. This is a 26.75 percent decrease over sales of $187.300 million

Workday shares are trading lower after the company reported Q2 financial results and cut its FY27 sales guidance below estimates. Also, the company issued Q3 sales guidance below estimates.

Rubrik Sees Q3 Adj EPS $0.07-$0.09 vs $0.06 Est; Sees Sales $429.000M-$431.000M vs $418.285M Est

Rubrik (NYSE:RBRK) is looking for Q3 Adj EPS of $0.07-$0.09 vs $0.06 analyst estimate. sees sales of $429.000 million-$431.000 million vs $418.285 million analyst estimate.

Autodesk shares are trading lower after the company reported Q2 financial results and issued Q3 EPS guidance below estimates. Also, the company narrowed its FY27 adjusted EPS guidance with its midpoint below estimates.

SentinelOne Lowers FY2027 Adj EPS Guidance from $0.32-$0.38 to $0.30-$0.32 vs $0.35 Est; Raises FY2027 Sales Guidance from $1.195B-$1.205B to $1.202B-$1.207B vs $1.205B Est

SentinelOne (NYSE:S) lowers FY2027 Adj EPS guidance from $0.32-$0.38 to $0.30-$0.32 vs $0.35 analyst estimate. Raises FY2027 sales outlook from $1.195 billion-$1.205 billion to $1.202 billion-$1.207 billion vs $1.205

Workday Board Authorizes Open-Ended Repurchase of Up to An Additional $4B of Its Outstanding Shares Of Class A Common Stock

Workday welcomed new customers including BWX Technologies, Inc., Guess, KPMG LLP, and S-E-B, and expanded existing relationships with Caterpillar, Delivery Hero (Talibat), Lithia & Driveway, Merck & Co., Inc.,

Pasqal Completes Business Combination With Bleichroeder Acquisition Corp. II, To Begin Nasdaq Trading As “PSQL” Aug. 28

Pasqal Holding SA expects its ordinary shares to begin trading on Nasdaq under the ticker symbol "PSQL" on August 28thTransaction establishes a strong capital foundation for Pasqal as a public company, with

SentinelOne Sees Q3 Adj EPS $0.08-$0.09 vs $0.11 Est; Sees Sales $309.000M-$311.000M vs $309.442M Est

SentinelOne (NYSE:S) is looking for Q3 Adj EPS of $0.08-$0.09 vs $0.11 analyst estimate. sees sales of $309.000 million-$311.000 million vs $309.442 million analyst estimate.

Alto Neuroscience Promotes Nick Smith To President, CFO, Effective Aug. 26

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief

Elastic Raises FY2027 Adj EPS Guidance from $3.21-$3.29 to $3.29-$3.37 vs $3.24 Est; Raises FY2027 Sales Guidance from $1.985B-$2.000B to $1.998B-$2.010B vs $1.993B Est

Elastic (NYSE:ESTC) raises FY2027 Adj EPS guidance from $3.21-$3.29 to $3.29-$3.37 vs $3.24 analyst estimate. Raises FY2027 sales outlook from $1.985 billion-$2.000 billion to $1.998 billion-$2.010 billion vs $1.993

Marvell Tech Sees Q3 GAAP EPS $0.48-$0.58 vs $0.52 Est

Marvell Tech (NASDAQ:MRVL) is looking for Q3 GAAP EPS of $0.48-$0.58 vs $0.52 analyst estimate.